KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Accumulated Expenses: 2014-2025

Historic Other Accumulated Expenses for Travere Therapeutics (TVTX) over the last 11 years, with Sep 2025 value amounting to $5.4 million.

  • Travere Therapeutics' Other Accumulated Expenses rose 2.31% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 2.31%. This contributed to the annual value of $17.1 million for FY2024, which is 226.64% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Other Accumulated Expenses is $5.4 million, which was down 62.54% from $14.3 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Other Accumulated Expenses registered a high of $17.1 million during Q4 2024, and its lowest value of $5.2 million during Q3 2024.
  • Over the past 3 years, Travere Therapeutics' median Other Accumulated Expenses value was $5.4 million (recorded in 2025), while the average stood at $8.2 million.
  • As far as peak fluctuations go, Travere Therapeutics' Other Accumulated Expenses crashed by 43.09% in 2022, and later surged by 226.64% in 2024.
  • Travere Therapeutics' Other Accumulated Expenses (Quarterly) stood at $6.2 million in 2021, then dropped by 7.53% to $5.7 million in 2022, then fell by 8.48% to $5.2 million in 2023, then soared by 226.64% to $17.1 million in 2024, then climbed by 2.31% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $14.3 million for Q2 2025, and $15.8 million during Q1 2025.